Form 4: Quince Therapeutics Director Margaret McLoughlin Opts for Stock Options Over Cash Retainer

Quince Therapeutics, Inc. director Margaret McLoughlin was granted 27,000 stock options with an exercise price of $1.09, vesting in one year, as part of her 2025 annual director compensation.

Summary

• Margaret McLoughlin, a Director of Quince Therapeutics, Inc. (QNCX), acquired 27,000 stock options.
• These options have an exercise price of $1.09 per share.
• The options were granted on June 4, 2025, and will vest 100% on the one-year anniversary of the grant date, which is June 4, 2026.
• The expiration date for these options is June 4, 2035.
• Ms. McLoughlin elected to receive these stock options instead of the annual director cash retainer for 2025, consistent with the company's Outside Director Compensation Policy.

Sentiment

Score: 6

Explanation: Slightly positive as it indicates alignment of director's interests with shareholders through equity compensation, a common and generally favorable practice.

Positives

• The director's election to receive stock options instead of cash aligns her interests more closely with those of shareholders, as her compensation becomes tied to the company's stock performance.

Future Outlook

NA

Industry Context

This is a standard compensation practice in the biotechnology and pharmaceutical industries, where equity-based compensation is common to attract and retain talent and align interests with long-term company performance.

Comparison to Industry Standards

• The practice of granting stock options to directors in lieu of cash retainers is a common corporate governance strategy, particularly in growth-oriented sectors like biotechnology, as seen in companies such as Moderna (MRNA) or BioNTech (BNTX) which frequently use equity to incentivize leadership.
• The vesting schedule of one year is typical for annual director grants, aiming to retain directors for at least that period.
• The exercise price being a specific value ($1.09) indicates it's likely tied to the stock price at the time of grant, a standard practice for incentive stock options.

Corporate Governance

Related Party Transactions

• The grant of 27,000 stock options to Margaret McLoughlin, a director, constitutes a related party transaction as it involves compensation provided by the company to a member of its board.

Stakeholder Impact

• Shareholders: The equity compensation aligns the director's financial interests with shareholder value creation, potentially leading to more shareholder-centric decision-making.

Next Steps

• The 27,000 stock options will vest 100% on June 4, 2026.
• The director may exercise these options at any time after vesting until their expiration on June 4, 2035.

Key Dates

Keywords

Quince Therapeutics, QNCX, SEC Form 4, Insider Transaction, Stock Options, Director Compensation, Equity Compensation, Margaret McLoughlin, Biotechnology, Pharmaceuticals